In fact, about 5% of all breast cancers bear a BRCA1/2 germline pathogenic variant (PV) [6], being a tissue sensitive to PARP inhibitors [7], and thus treatment with this type of molecule is feasible. Here, BRCA1 is linked to breast carcinoma.